April 22, 2026 · 8 min · JOURNAL
Compounded vs Brand-Name Semaglutide: What the Real Differences Are
Compounded semaglutide is cheaper than Wegovy or Ozempic, but it is also less regulated. Here is what compounding pharmacies do differently, what the FDA has flagged, and how to evaluate whether a compounded option is right for you.
Written and medically reviewed by the Elysiv Life clinical team — board-certified Nurse Practitioners.
KEY TAKEAWAYS
- ✓Brand-name semaglutide (Ozempic, Wegovy) is FDA-approved with standardized manufacturing. Compounded semaglutide is made by a 503A or 503B compounding pharmacy under different rules.
- ✓Compounded semaglutide is legal when the brand product is on the FDA shortage list. The shortage status changes over time — not all compounded options are appropriate at all times.
- ✓Quality varies by pharmacy. Vetted compounding pharmacies test for sterility and potency; less-vetted ones do not. Always know your pharmacy.
- ✓Salt forms and excipients in compounded semaglutide may differ from brand. The FDA has issued warnings about non-base semaglutide salts.
- ✓Cost-wise, compounded options can be 50-80% cheaper than brand. That margin matters for patients without insurance coverage — but only if the source is trustworthy.
Compounded semaglutide is everywhere right now, and the price gap versus Wegovy or Ozempic is real. So is the confusion. Compounding is a legitimate part of medicine — but "compounded" is not a discount version of the brand drug, and the differences are worth understanding before you inject anything.
What compounding actually is
Brand-name semaglutide is FDA-approved and manufactured to a single standardized specification. Compounded semaglutide is prepared by a compounding pharmacy — a 503A pharmacy serving individual prescriptions, or a larger 503B outsourcing facility — under a different regulatory framework. Compounded drugs are not FDA-approved as products; the FDA does not verify their safety, effectiveness, or quality the way it does for brand medications.
When it is even legal
Compounding a copy of an approved drug is generally permitted when that drug is on the FDA shortage list. Shortage status changes over time — semaglutide and tirzepatide have moved on and off it — and when a drug comes off the shortage list, the legal basis for compounding a copy narrows. This is a moving target, which is one reason a prescribing relationship matters more than a one-time order.
The quality question
Quality varies enormously by pharmacy. Reputable compounders test for sterility and potency and document their sourcing; less scrupulous operations do not. The FDA has specifically warned about compounded products using semaglutide salt forms (such as semaglutide sodium or acetate) rather than the base, because the salt forms have not been shown to be safe and effective. If you cannot name your pharmacy and confirm it tests its products, that is a problem.
How to evaluate a compounded option
Ask four things: Is the pharmacy licensed and, ideally, a 503B facility? Does it use base semaglutide, not a salt form? Does it provide sterility and potency testing? And is a real clinician overseeing your dose and monitoring? If the answer to any is no, the savings are not worth it. Our comparison of Wegovy vs Zepbound covers the brand side of the same decision.
At Elysiv, we prescribe brand-name when your insurance or budget supports it, and only use compounded alternatives through pharmacies we have vetted for sterility, potency testing, and clinical-grade standards — never a mystery vial from an unverified source.
SOURCES
RELATED AT ELYSIV
We prescribe brand-name when your insurance or budget supports it, and only use compounded alternatives through pharmacies we have vetted for sterility, potency testing, and clinical-grade compounding standards.
GLP-1 Care program
